Profile data is unavailable for this security.
About the company
Stryker Corporation (Stryker) is a medical technology company. It offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. It operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products. It also develops neurointerventional devices for the treatment of intracranial aneurysms. It offers Fortress, a modular wall system for hospitals and ambulatory surgery centers. It specializes in soft tissue fixation products and delivering AI-assisted virtual care workflows.
- Revenue in USD (TTM)21.39bn
- Net income in USD3.45bn
- Incorporated1946
- Employees52.00k
- LocationStryker Corp1941 STRYKER WAYPORTAGE 49002United StatesUSA
- Phone+1 (269) 385-2600
- Fax+1 (269) 385-1062
- Websitehttps://www.stryker.com/
Mergers & acquisitions
| Acquired company | SYK:NYQ since announced | Transaction value |
|---|---|---|
| Serf SAS | 25.81% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic PLC | 32.58bn | 3.93bn | 113.03bn | 95.00k | 29.64 | 2.36 | 17.15 | 3.47 | 2.97 | 2.97 | 24.66 | 37.39 | 0.3609 | 2.03 | 5.51 | 342,915.80 | 4.38 | 4.57 | 4.92 | 5.14 | 65.53 | 66.75 | 12.14 | 13.49 | 1.61 | 12.10 | 0.3665 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.23bn | 1.83bn | 121.59bn | 48.00k | 66.76 | 5.96 | 39.83 | 7.98 | 1.24 | 1.24 | 10.29 | 13.85 | 0.4307 | 1.94 | 6.72 | 317,250.00 | 5.16 | 2.50 | 6.07 | 2.91 | 69.08 | 68.84 | 11.98 | 6.47 | 1.14 | 5.73 | 0.339 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.39bn | 3.45bn | 137.68bn | 52.00k | 40.30 | 6.97 | 30.75 | 6.44 | 8.97 | 8.97 | 55.62 | 51.86 | 0.5589 | 1.60 | 6.22 | 411,326.90 | 9.01 | 6.60 | 10.94 | 7.84 | 64.05 | 63.99 | 16.12 | 13.13 | 0.9531 | -- | 0.3821 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Intuitive Surgical, Inc. | 7.57bn | 2.09bn | 171.00bn | 13.68k | 82.78 | 11.65 | 65.82 | 22.58 | 5.82 | 5.82 | 21.06 | 41.40 | 0.4957 | 2.10 | 7.52 | 553,707.30 | 13.81 | 12.42 | 15.42 | 13.83 | 66.86 | 67.60 | 27.86 | 26.31 | 4.22 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Danaher Corp | 23.57bn | 4.06bn | 196.37bn | 61.00k | 50.00 | 3.95 | 31.32 | 8.33 | 5.44 | 5.63 | 31.63 | 68.92 | 0.2884 | 3.29 | 6.23 | 386,360.70 | 4.96 | 5.93 | 5.47 | 6.56 | 59.16 | 58.79 | 17.21 | 19.11 | 1.04 | 17.19 | 0.2542 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Abbott Laboratories | 40.73bn | 5.56bn | 199.88bn | 114.00k | 36.15 | 5.08 | 22.70 | 4.91 | 3.18 | 3.18 | 23.29 | 22.60 | 0.5565 | 2.65 | 6.25 | 357,236.80 | 7.59 | 7.72 | 9.44 | 9.39 | 55.43 | 56.73 | 13.65 | 14.39 | 1.18 | 25.44 | 0.2716 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 30.55m | 8.02% |
| Greenleaf Asset Management, Inc.as of 06 Aug 2024 | 21.05m | 5.52% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 17.12m | 4.49% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 14.27m | 3.74% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 11.21m | 2.94% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 10.99m | 2.88% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 7.33m | 1.92% |
| Fundsmith LLPas of 30 Jun 2024 | 7.24m | 1.90% |
| Geode Capital Management LLCas of 30 Jun 2024 | 6.74m | 1.77% |
| JPMorgan Investment Management, Inc.as of 30 Jun 2024 | 6.65m | 1.75% |
